On June 1, 2022 EpicentRx, Inc, a privately-held clinical-stage biotechnology company at the forefront of developing oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, reported that data from a Phase 2 randomized clinical trial with RRx-001 in first line head and neck cancer has been selected for a poster presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting on June 3-7, 2022, in Chicago, Illinois (Press release, EpicentRx, JUN 1, 2022, View Source [SID1234615382]). Positive results from the completed Phase 2 study called PREVLAR that was carried out in collaboration with Dr. Stephen Sonis, Distinguished Faculty member at the Dana-Farber Cancer Institute and CMO of Primary Endpoint Solutions and a leading expert in cancer-related oral mucositis, will be presented, highlighting the anti-inflammatory and antioxidant properties of RRx-001 as well as plans to initiate a follow-on trial called KEVLAR.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details on the company’s poster presentation are below:
Abstract Title: Phase 2 pilot trial of RRx-001 as an anti-mucositis agent in head and neck cancer patients treated with chemoradiation (PREVLAR)
Session Title: Head and Neck Cancer
Abstract Number for Publication: 6078
Session Date and Time: Monday, June 6, 2022, 1:15 PM-4:15 PM CDT
About RRx-001
RRx-001 leads EpicentRx’s CyNRGY platform as a first-in-class investigational treatment sourced from an exclusively licensed portfolio of aerospace-derived small molecules. RRx-001 is a multifaceted treatment with a dual-functioning mechanism that starts under "normal" conditions, or healthy tissues that are reasonably well-oxygenated, and the activity changes in poorly oxygenated (hypoxic) tissues, which is a distinguishing characteristic of cancerous tumors.